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Sébastien Lustig2,6, Florence Ader1,2,3, Benoit Martha4, Frédéric Laurent2,3,7, Christian Chidiac1,2,3,
Tristan Ferry1,2,3* and on behalf of the Lyon BJI Study group
Abstract
Background: Even if daptomycin does not have approval for the treatment of bone and joint infections (BJI), the
Infectious Diseases Society of America guidelines propose this antibiotic as alternative therapy for prosthetic joint
infection. The recommended dose is 6 mg/kg/d, whereas recent data support the use of higher doses in these patients.
Methods:We performed a cohort study including consecutive patients that have received daptomycin >6 mg/kg/d for
complex BJI between 2011 and 2013 in a French regional reference center. Factors associated with treatment failure were
determined on univariate Cox analysis and Kaplan-Meier curves.
Results: Forty-three patients (age, 61 ± 17 years) received a mean dose of 8 ± 0.9 mg/kg/d daptomycin, for a mean 81 ±
59 days (range, 6–303 days). Most had chronic (n = 37, 86 %) implant-associated (n = 37, 86 %) BJI caused by coagulase-
negative staphylococci (n = 32, 74 %). A severe adverse event (SAE) occurred in 6 patients (14 %), including 2 cases of
eosinophilic pneumonia, concomitant with daptomycin Cmin >24 mg/L. Outcome was favorable in 30 (77 %) of the 39
clinically assessable patients. Predictors for treatment failure were age, non-optimal surgery and daptomycin withdrawal
for SAE.
Conclusions: Prolonged high-dose daptomycin therapy was effective in patients with complex BJI. However, optimal
surgery remains the cornerstone of medico-surgical strategy; and a higher incidence of eosinophilic pneumonia than
expected was recorded.
Keywords: Daptomycin, Bone and joint infection, Eosinophilic pneumonia
Background
Bone and joint infections (BJI) include very heteroge-
neous clinical entities, with different therapeutic strat-
egies and prognoses. Some, such as uncomplicated
childhood osteomyelitis, are easy to treat, as short-
course antimicrobial therapy without surgery is classic-
ally associated with excellent prognosis. In contrast, in
some situations such as chronic implant-associated BJI,
the pathogen is difficult to eradicate, leading to high
rates of relapse and morbidity despite aggressive surgical
strategy and prolonged intravenous antibiotic therapy. In
such cases, team-work in tertiary care centers is required
to determine optimal surgical management so as to limit
treatment failure, motor disability and risk of amputa-
tion. The choice of antimicrobial therapy is also challen-
ging, requiring consideration of: (i) the problem of bone
diffusion [1]; (ii) the necessity of using antimicrobials ac-
tive against bacterial biofilms [2]; (iii) the growing
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of severe adverse events (SAE) in response to first-line
antimicrobials in these patients [3]. Consequently, off-
label use of recently developed antimicrobials, such as
daptomycin, is frequently required as salvage therapy in
complex BJI.
Daptomycin is a cyclic lipopeptide with rapid bacteri-
cidal action against Gram-positive bacteria, and is ap-
proved for complicated skin and skin-structure infection
(4 mg/kg/day intravenously) and Staphylococcus aureus
bacteraemia and/or right-side endocarditis (6 mg/kg/d).
Beyond these FDA and European-approved indications,
daptomycin is increasingly used in BJI, as: (i) Gram-
positive cocci are the most frequent pathogens in BJI;
(ii) staphylococci exhibit growing resistance to beta-
lactams and glycopeptides; (iii) a randomized controlled
trial supported the use of daptomycin in these patients
[4]. Consequently, daptomycin has been proposed as an
alternative therapeutic option in patients with staphylo-
coccus or enterococcus prosthetic joint infection in the
recent Infectious Diseases Society of America (IDSA)
guidelines (6 mg/kg/d) [5]. As bone penetration of dap-
tomycin is limited, some authors proposed higher doses
in BJI: i.e., 8 mg/kg/d [6]. This attitude is supported by
the retrospective post-marketing Eu-CORE® study, but
prospective data are lacking, especially in patients at
high risk of relapse receiving prolonged daptomycin
therapy [7].
In this context, the present cohort study aimed to as-
sess the safety and efficacy of prolonged high-dose
(>6 mg/kg/d) daptomycin salvage therapy in patients
with complex BJI, focusing on daptomycin-related SAEs
such as rhabdomyolysis or eosinophilic pneumonia, and
to determine risk-factors for treatment failure.
Methods
We performed a cohort study including consecutive pa-
tients that have received daptomycin >6 mg/kg/d as al-
ternative therapy for complex BJI from January 2011 to
July 2013 in a French regional reference center. Patients
with creatinine clearance <30 mL/min were excluded.
Diagnosis of BJI was based upon clinical and/or imaging
evidence, and culture of microorganisms from synovial
fluid or periprosthetic tissue (more than two specimens
for bacteria from skin flora: e.g., coagulase-negative
staphylococci, Corynebacterium spp, Propionibacterium
acnes). Infection was classified as “chronic” when there
was a delay of one month between the bone contamin-
ation (previous surgery) and diagnosis. In line with the
definition given by the Health-care Supply Office (Direc-
tion Générale de l’Offre de Soins, DGOS) of the French
Health Ministry (Ministère des Affaires Sociales et de la
Santé), BJI was considered complex in the following cir-
cumstances: (i) relapsing BJI; and/or (ii) intolerance tofirst-line antimicrobial therapy; and/or (iii) requirement
of large bone resection and/or reconstruction; and/or
(iv) multi-drug resistant pathogen limiting therapeutic
opportunities, such as a glycopeptide-resistant Gram-
positive isolate.
Susceptibility to glycopeptides and daptomycin was
assessed in methicillin-resistant staphylococci based on
the criteria of the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST: Breakpoint tables
for interpretation of minimum inhibitory concentrations
[MICs] and zone diameters, version 4.0), if the strain
was available at the time of daptomycin prescription.
Notably, daptomycin MICs were determined by the E-
test® method. In patients with implant-related infection,
surgical treatment was considered optimal if based on
French and IDSA guidelines: i.e., debridement-lavage
and implant retention followed by antimicrobial therapy
in acute infection, and implant removal (with or without
reimplantation) followed by antimicrobial therapy in
chronic infection. In patients with non-implant-related
BJI, surgery was considered optimal when large debride-
ment including bone resection was performed when re-
quired. Daptomycin was administered intravenously
once daily by 30-min infusion.
All patients were scheduled for inclusion in the “safety
analysis”. Only patients for whom at least two cultures
were positive for Gram-positive micro-organisms from
deep surgical specimens or joint-aspiration fluid were to
be included in the “efficacy analysis”. The use of high
doses of daptomycin entailed particular focus on
daptomycin-related adverse events (AE), which were sys-
tematically collected and assessed on the Common Ter-
minology Criteria for Adverse Events (CTCAE: version
3.0, published 9 August 2006). AEs were classified as
mild (CTCAE stage 1), moderate (stage 2) or SAE
(stages 3, 4 and 5). Standard biological testing, including
blood creatine kinase (CK), was performed at least once
a week. After October 2012, daptomycin trough plasma
concentration (Cmin) was determined monthly for all pa-
tients, and additionally in case of AEs directly implicat-
ing daptomycin (i.e., at onset of elevated blood CK or of
eosinophilic pneumonia), to detect any patients with
daptomycin trough levels (Cmin) over 24 mg/L. Cmin was
determined 24 h after daptomycin injection (just before
reinjection, if performed) using a validated HPLC process
developed in the laboratory and a diode array UV de-
tector. Cmin > 24 mg/L was considered an overdose, as the
risk of high CPK levels (with or without symptoms of my-
opathy) is greater above this threshold [8].
Treatment failure was defined as worsening or new
clinical signs related to persistent and/or new infection
at the BJI site. Treatment failure implicating daptomycin
included relapse with the same Gram-positive strain,
and super-infection due to another Gram-positive strain.
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was not considered as treatment failure implicating dap-
tomycin. Determinants of treatment failure were ex-
plored by univariate log-rank test and unadjusted Cox
analysis. Statistical analysis used SPSS 17.0 software
(SPSS Inc, Chicago, IL, USA). The research was con-
ducted in accordance with the Declaration of Helsinki
and national and institutional standards. The study re-
ceived the approval of the French South-East II and III
ethics committee with the reference number CAL2011-
021 and n°QH 20/2014. In accordance with French legis-
lation, written informed consent was not required for
any part of the study, as (i) daptomycin was used as sal-
vage therapy in the usual care of patients addressed to
our regional reference center for complex BJI; (ii) pa-
tients were informed orally and by letter that data were
being collected using a national database established by
the DGOS (in line with ruling n°2012–220 of the French
national data protection commission: Commission Natio-
nale de l’Informatique et des Liberté). The study was reg-
istered to ISRCTN (number ISRCTN14244698).
Results
Baseline patient characteristics
During the study period, 43 complex BJIs were treated
by daptomycin (>6 mg/kg/d) as salvage therapy in 42 pa-
tients. In 40 cases (93 %), osteomyelitis was diagnosed
based on clinical signs: fistula (n = 26, 60 %), pain (n =
21, 49 %), inflammatory aspect (n = 17, 40 %), fever (n =
9, 21 %), abscess (n = 5, 12 %), osteoarthritis (n = 2, 5 %),
or sepsis (n = 1, 2 %). Three patients (7 %) were asymp-
tomatic: in 2 cases, daptomycin was prescribed for a
super-infection documented on an explanted ortho-
paedic device; in the third, osteomyelitis was diagnosed
from radiologic abnormalities.
Criteria for complexity were: (i) relapsing BJI in 27 pa-
tients (62 %); (ii) intolerance to first-line antimicrobial
therapy in 42 (98 %); (iii) requirement of large bone re-
section and/or reconstruction in 37 (86 %); and (iv) in-
fection with a glycopeptide-resistant Gram-positive
strain in 22 (51 %). Glycopeptides were the most com-
mon prior treatment (n = 37, 86 %). The most common
reason for discontinuing prior antibiotic therapy was the
occurrence of a side-effect (n = 23, 53 %), including aller-
gic reaction (n = 17, 40 %) and/or renal failure related to
vancomycin overdose (n = 7, 16 %). Baseline characteris-
tics are summarized in Table 1.
Microbiology and daptomycin prescription patterns
Culture results from deep samples included 33 bone
samples (77 %), 5 joint aspirate samples (12 %), and 2
other deep samples (5 %). Coagulase-negative staphylo-
coccus was implicated in 32 patients (74 %), S. aureus in
11 (26 %), P. acnes in 8 (19 %), Corynebacterium spp. in4 (9 %) and Enterococcus in 3 (7 %). Five of these pa-
tients (12 %) were co-infected with Gram-negative ba-
cilli, and 3 with fungi (8 %). Infection was polymicrobial
in 23 cases (59 %). Twenty-seven of the 32 coagulase-
negative staphylococci isolates (84 %) were methicillin-
resistant; vancomycin MIC was >2 mg/L and equal to
2 mg/L in 10 (31 %) and 12 (39 %) isolates, respectively;
and 18/32 (56 %) isolates were resistant to teicoplanin.
Daptomycin E-test® results were available in 25 isolates
among the methicillin-resistant strains (93 %): all were
susceptible to daptomycin, with MIC values ranging
from 0.064 to 1 mg/L (mean, 0.33 ± 0.27 mg/L).
In S. aureus, methicillin resistance was detected in 1
patient (9 %), with conserved susceptibility to glycopep-
tides, and daptomycin MIC of 0.125 mg/L.
Daptomycin was administered at doses ranging from
6.5–10 mg/kg/d (mean, 8 ± 0.9 mg/kg/d). Thirteen pa-
tients (30 %) received >8 mg/kg/d. Daptomycin was in-
cluded in anti-Gram-positive combination therapy in 37
patients (86 %), most commonly associated with fosfo-
mycin (n = 15, 35 %), rifampin (n = 9, 21 %) or clindamy-
cin (n = 5, 12 %). Fourteen patients (33 %) received
daptomycin treatment as outpatient parenteral antibiotic
therapy.
Safety analysis
The primary reason for stopping daptomycin was com-
pletion of therapy (37 patients, 86 %). Mean treatment
duration was 81 ± 59 days (range 6–303 days). During
daptomycin-based antimicrobial therapy, 17 patients (40
%) experienced 26 AEs (Table 2). Eight patients (16 %)
experienced mild AEs, 2 (5 %) moderate AEs and 6 (14
%) SAEs, none of which were life-threatening. AEs oc-
curred after a mean 56 ± 48 days’ daptomycin therapy
(range, 6–180 days). All 6 SAEs (Table 3) led to dapto-
mycin withdrawal (Fig. 1). Three patients (7 %) experi-
enced mild transient asymptomatic increase in CK; none
were receiving statins. Three patients developed pneu-
monia, including two cases of certain eosinophilic pneu-
monia directly implicating daptomycin. These two
patients had pulmonary infiltrates and bronchoalveolar
fluid with eosinophils (35 % and 11 %, respectively;
Fig. 2); of note, both were receiving more than 8 mg/kg/d
daptomycin (8.4 and 8.7 mg/kg/d, respectively), and dap-
tomycin Cmin > 24 mg/L was associated (Table 3). Cox
univariate analysis and Kaplan Meier curves showing the
cumulative probability of SAEs during daptomycin-based
therapy showed no significant differences between pa-
tients receiving 6–8 mg/kg/d vs. > 8 mg/kg/d (Fig. 3, panel
A). Daptomycin Cmin was assessed 52 times in 20 patients
(47 %) after October 2012; 1 case showed daptomycin
Cmin > 24 mg/L, with asymptomatic elevation of blood
CK. Of note, asymptomatic transient daptomycin Cmin >
24 mg/L was detected in 3 other patients, without
Table 1 Demographic characteristics of 43 patients who
received daptomycin-based antimicrobial therapy
Characteristic (n, %)
Gender
Female 18 (42)
Male 25 (58)
Mean age, years (range) 61 (18–88)
Age groups
< 65 years 25 (58)
≥ 65–< 75 years 8 (19)
≥ 75 years 10 (23)
Mean body weight, kg (range) 75 (32–110)
Mean body mass index (range) 27 (14–43)
BMI≥ 25, < 30 9 (21)
BMI≥ 30 14 (33)
Ethnicity (caucasian) 42 (98)
Active smoking 10 (23)
Underlying diseases
Hypertension 17 (40)
Diabetes mellitus 5 (12)
Cardiovascular disease 13 (30)
Cancer 6 (14)
Creatinine clearance (MDRD) 30–60 mL/min 3 (7)
Immunosuppression 4 (9)
Mean ASA score (range) 2.2 (1–4)
Past episode of BJI on the same site 27 (63)
Anatomical site of infection
Knee 12 (28)
Hip 9 (21)
Lower limb 9 (21)
Rachis 8 (19)
Upper limb 2 (5)
Other 1 (2)
Chronic osteomyelitis 37 (86)
Physiopathology of osteomyelitis
Post-operative 41 (95)
Hematogenous infection 2 (5)
Pressure ulcer 2 (5)
Orthopedic device
Prosthesis 23 (53)
Osteosynthesis device 14 (33)
None 6 (14)
Previous exposition to antimicrobials for the
index BJI before daptomycin prescription
Glycopeptides 37 (86)
Fluoroquinolones 27 (63)
Rifampin 25 (58)
Table 1 Demographic characteristics of 43 patients who
received daptomycin-based antimicrobial therapy (Continued)
Clindamycin, pristinamycin 18 (42)
Piperacillin tazobactam 15 (35)
Cephalosporins 13 (30)
Fosfomycin 13 (30)
Oxacillin, cloxacillin 12 (28)
Aminoglycosids 9 (21)
Fucidic acid 7 (16)
Linezolid 5 (12)
Others 18 (42)
Data are n (%) unless otherwise indicated
ASA American Society of Anesthesiologists, BJI Bone and joint infection, BMI
Body mass index, MDRD Modification of the diet in renal disease
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ive of occurrence of SAE (6 events; HR, 1.092; 95 % CI,
0.950–1.254), whereas it was predictive of occurrence of
mild to severe AEs (8 events; HR, 1.037; 95 % CI, 1.002–
1.073).
Efficacy analysis
Four cases of osteitis were excluded from the efficacy
analysis (Fig. 1). Two of the 39 patients included (5 %)
underwent no surgery, because of severe underlying dis-
ease. Surgery was considered optimal in 24 patients (62
%). During follow-up (387 ± 243 days), treatment failure
was recorded for 9 patients (23 %) (Fig. 1), all concern-
ing implant-associated BJI. None of the strains involved
developed daptomycin MIC elevation during the study
period. All patients in whom daptomycin was discontin-
ued experienced relapse. Univariate Cox analysis and
Kaplan-Meier curves showed that dose exceeding 8 mg/
kg/day was not associated with better outcome (Table 4;
Fig. 3, panel B). Three factors were significantly associ-
ated with treatment failure: age (hazard ratio [HR], 1.89;
95 % confidence interval (CI), 1.03–3.47), non-optimal
surgery (HR, 3.63, 95 % CI, 0.91–14.73) and SAE leading
to daptomycin discontinuation (HR, 4.84; 95 % CI, 1.17–
20.05) (Table 4; Fig. 3, panel C and D).
Discussion
Despite its non-comparative, non-randomized, single-
center design, this cohort study provides important data
concerning off-label use of prolonged high-dose dapto-
mycin therapy in complex BJI, reflecting the real-life use
of daptomycin in a BJI referral center. Daptomycin ther-
apy in patients with complex BJI shows a high rate of
treatment success (77 %), despite the patient population
being at high risk of relapse. Age, non-optimal surgery
and daptomycin discontinuation for serious adverse
events were the three determinants of treatment failure.
Daptomycin was safe, but a higher incidence of
Table 2 Adverse events potentially related to the daptomycin-based antimicrobial therapy (n = 43) that occurred in 17 of the 43
included patients. Daptomycin dose is expressed in mg/kg/d. AEs onsets are notified in days
Adverse events n (%) Daptomycin dose
(mean, range)
AE onset
(mean, range)
Daptomycin
withdrawal
Companion drug
withdrawal
Hematologic disorders 12 (28) 7,8 (7–9) 44 (7–92) 4/12 3/12
Hypereosinophilia 6 (14) 7,8 (7–9) 43 (10–92) 3/6 1/6
Neutropenia 4 (9) 7,8 (7–9) 73 (49–88) 1/4 2/4
Increased blood CPK 4 (9) 7,5 (7–8) 49 (9–92) 2/4 2/4
PICC thrombosis 3 (7) 8,3 (7–9) 39 (12–79) 1/3 0/3
Hepatic disorders 3 (7) 8,2 (7,5–9) 71 (13–112) 0/3 1/3
Eosinophilic pneumonia 2 (5) 8,5 (8–9) 17 (6–23) 2/2 1/1
Increased blood creatinine 1 (2) 8 8 1 1
Pancreatitis 1 (2) 8 180 0 1
AE, Adverse event, CK, Creatine kinase, PICC, Peripherally inserted central catheter
Roux et al. BMC Infectious Diseases  (2016) 16:83 Page 5 of 9eosinophilic pneumonia than expected was recorded, in
contexts of daptomycin Cmin > 24 mg/L.
Daptomycin does not have approval for the treatment
of BJI by the US and European authorities. However,
based on retrospective data and one randomized con-
trolled trial, it was proposed as an alternative option in
patients with staphylococcus or enterococcus prosthetic
joint infection in the recent IDSA guidelines, at the
standard dose of 6 mg/kg/d [4, 5, 7]. Recent reports of
poor daptomycin bone penetration encourage the use of
higher doses [6]. In addition to these pharmacological
studies, doses up to 8 mg/kg are supported by in vitro
[9, 10] and in vivo studies [11–13] High doses have been
described in retrospective studies [14–16], but prospect-
ive studies including patients receiving high doses of
daptomycin are crucial to determine efficacy and safety
in BJI.
Concerning safety, patients with BJI are particularly
exposed to serious adverse events, as most antimicro-
bials are used in combination, at high doses and for sev-
eral weeks or months [3]. In the present study, 40 % of
patients experienced at least one AE during treatment,
which is notably higher than in previous reports [7]. This
difference can probably be explained by longer treatment
duration (81 days, versus 28 days in the EU-CORESMTable 3 Serious adverse events (SAE) occurring in 6 patients under
Patient Dose
(mg/kg/d)
Additional
antibiotic
SAE
1 8,8 Rifampicin* Neutropenia
2 7,1 Rifampicin Hypereosinophilia
3 8,4 Rifampicin Eosinophilic pneumonia, rhabdom
4 8,7 Pristinamycin PICC thrombosis
5 8,7 None Eosinophilic pneumonia
6 7,8 Linezolid Acute renal failure
In bold: SAE directly attributed to daptomycin
NA Not available, PICC Peripherally inserted central catheter, SAE Serious adverse ev
*Rifampicin can induce both neutropenia and eosinophiliadatabase), as AEs occurred after a mean 56 days. Despite
this high AE rate, only 6 patients experienced an SAE that
led to daptomycin discontinuation, which is consistent
with the 10 % rate of toxicity-related daptomycin with-
drawal observed in a recent retrospective series of 20 pa-
tients [16]. Of note, 2 of the 6 presented confirmed
eosinophilic pneumonia (5 % of patients), which is more
than expected, as eosinophilic pneumonia is considered to
be an infrequent daptomycin-related SAE: 0.5 % of pa-
tients receiving daptomycin in the retrospective post-
marketing Eu-CORE® study experienced eosinophilic
pneumonia, and a recent review of the literature reported
only 24 published cases [17]. The pathophysiology of
daptomycin-associated eosinophilic pneumonia is unclear,
and it is unknown whether high doses of daptomycin
might contribute to the occurrence of eosinophilic pneu-
monia. In vitro investigations suggest that hydrophilic
proteins contained in the pulmonary surfactant (particu-
larly surfactant protein C) bind to daptomycin, inhibit its
antibacterial activity and facilitate the formation of surfac-
tant aggregates [18]. The relation between eosinophilic
pneumonia and daptomycin Cmin > 24 mg/L has to be ex-
plored, especially as there was daptomycin Cmin > 24 mg/L
in both patients with eosinophilic pneumonia. Dapto-
mycin Cmin > 24 mg/L in plasma may lead to drugdaptomycin-based antimicrobial therapy
SAE onset
(days)
Cmin at SAE
onset (mg/L)
Daptomycin
withdrawal
Companion drug
withdrawal
73 NA Yes Yes
92 NA Yes No
yolysis 10 134 Yes Yes
12 NA Yes No
23 38 Yes NA
8 NA Yes Yes
ent
Consecutive patients receiving Daptomycin >6 
mg/kg/d for
complex BJI (n=43)
4 patients 
excluded
(No deep sample 
available or only 
one deep sample 
positive for CNS)
Safety analysis
(n=43)
Efficacy analysis
(n=39)
6 (14%) daptomycin 
discontinuations for 
occurrence of SAE
9 (23%) 
Treatment 
failures
2 (5%) daptomycin-specific 
SAE (eosinophilic pneumonia 
rhabdomyolysis)
4 (9%) other SAE
4 (10%) relapses with 
the same strain
4 (10%) Gram-positive 
pathogen super-
infections
1 (3%) clinical 
relapse
Fig. 1 Flow chart of the cohort study. CNS, Coagulase negative staphylococci; SAE, Serious adverse event
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mation of surfactant aggregates, followed by eosino-
phil recruitment in lung parenchyma.
Moreover, 6 patients are presented in Table 3 with ser-
ious adverse events: 4 of them with dose higher than
8 mg/kg and 2 of them with dose higher than 7 mg/kg.
Variables associated with treatment failure did not in-
clude daptomycin dose lower than 8 mg/kg: regardingFig. 2 Chest X-ray (a, c) and computed tomography (b, d) for the two patthese data, we do not recommend to use doses higher
than 8 mg/kg/d.
Concerning efficacy, there was a high success rate (77
%) in a population at high risk of failure, especially as most
of our patients presented chronic relapsing implant-
associated BJI. This rate is consistent with the 75 % clin-
ical cure rate reported by Seaton et al. [7]. Of note, in the
present study: (i) daptomycin was used as second-lineients with eosinophilic pneumonia
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Fig. 3 Risk factors for failure and for severe adverse event
Table 4 Cox univariate analysis showing variables associated with treatment failure during daptomycin-based antimicrobial therapy
Variable n (%) unadjusted HR (95 % CI) p-value
Age (per 10 years) NA 1.89 (1.03–3.47) 0.041
Male sex 23 (59) 1.48 (0.25–1.48) 0.245
Obesity 12 (31) 1.06 (0.93–1.06) 0.932
ASA score NA 1.11 (0.79–1.11) 0.787
Smoking 13 (33) 0.91 (0.23–3.65) 0.896
Implant associated BJI 33 (85) 27.8 (0.02–40422.69) 0.371
Chronic BJI 5 (13) 1.15 (0.14–9.22) 0.894
Fistula 14 (36) 2.94 (0.60–14.43) 0.185
Relapsing BJI 15 (63) 5.50 (0.69–44.02) 0.108
S. aureus 11 (28) 0.59 (0.12–2.89) 0.517
No or non-optimal surgery 15 (38) 3.63 (0.91–14.73) 0.068
Previous treatment with glycopeptides 34 (87) 25.47 (0.01–142518.48) 0.462
Glycopeptide-resistant isolate 20 (51) 2.965 (0.70–12.58) 0.141
Daptomycin≤ 8 mg/kg/d 26 (67) 0.676 (0.18–2.55) 0.563
Daptomycin discontinuation for SAE 6 (15) 4.844 (1.17–20.05) 0.029
ASA American Society of Anesthesiologists, BJI bone and joint infection, HR, hazard ratio, NA not applicable (continuous variable), SAE serious adverse events
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posed to vancomycin; and (ii) half of the patients (22
patients, 51 %) were infected with Gram-positive patho-
gens with decreased susceptibility to glycopeptides (mostly
teicoplanin-resistant coagulase-negative staphylococci,
and 10 patients with vancomycin-resistant strains). These
two conditions have been reported to facilitate acquisition
of daptomycin-resistance during treatment in patients
with persistent bacteraemia or endocarditis [19–21]. Of
note, in the present series, patients experiencing treatment
failure did not show acquired daptomycin-resistance.
In the present study, as in others, age emerged as a
risk factor for treatment failure [22]. Interestingly, pa-
tients for whom daptomycin was withdrawn for SAE
were also at higher risk of treatment failure. This is eas-
ily explained, inasmuch as daptomycin was mostly used
as salvage therapy, and very few other treatment options
were available for our patients. Finally, non-optimal sur-
gery was also a risk factor for relapse, highlighting surgi-
cal management as the cornerstone of the treatment of
complex BJI. For instance, in patients with chronic
orthopaedic implant-associated infection, total removal
of the implant is required to limit bacterial persistence
[23]. Likewise, it is of the utmost importance to remove
the cement in patients with cemented prosthesis joint
infection. As removing the cement without inducing
bone fracture is usually challenging, particular improved
techniques, such as ultrasonic cement removal, are used
in reference centers, limiting the need for osteotomy
and preserving the bone stock that is essential for recon-
struction and reimplantation [24].
Consequently, in case of difficult-to-treat BJI, in which
relapse is associated with severe disabilities, the complex
choice of aggressive surgical strategies and the difficult
monitoring of off-label use of alternate therapies such as
daptomycin fully justify management in a regional refer-
ence center. The French care network created in 2008 by
the French Health Ministry (i.e., management of patients
with complex BJI in one of the 9 approved regional refer-
ence centers, in collaboration with primary public or
private-sector hospitals) may improve prognosis in one of
the most difficult-to-treat bacterial infections.
Conclusion
In conclusion, prolonged high-dose daptomycin was as-
sociated with a high success rate in our cohort of pa-
tients with complex BJI, partly because antimicrobial
therapy was associated with optimal surgery in a re-
gional reference cente, which is essential for the progno-
sis of complex BJI. Daptomycin was safe, although there
was a higher incidence of eosinophilic pneumonia than
expected, surprisingly in patients with daptomycin
Cmin > 24 mg/L. Based on our results, 8 mg/kg/d (and
no more) seems to be the adequate dose of daptomycinfor the treatment of BJI. Monitoring daptomycin levels
seems important in patients receiving high-doses of dap-
tomycin, to limit occurrence of adverse events.
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